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Background: It is controversial whether achieving stable disease
leads to a survival benefit and whether the importance of achieving
stable disease differs between cytotoxic agents and molecular tar-
geted agents. To examine these questions, the authors retrospec-
tively reviewed phase II and III studies in the second-line setting for
advanced non-small cell lung cancer using epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic
agents separately.
Methods: The authors chose 45 trials for the chemotherapy group
and nine for the EGFR TKI group by searching the PubMed
database. All nine trials in the EGFR TKI group concern gefitinib
and erlotinib.
Results: The median survival time increased 0.0375 month with
each 1% increase in stable disease rate (p  0.039), and each 1%
increase in response rate resulted in 0.0744 (p  0.001) month of
median survival time in the analysis combined with both cytotoxic
agents and EGFR TKIs. Main and interaction terms for EGFR TKI
treatment were not statistically significant. With respect to time to
progression, only response rate showed a statistically significant
relationship with survival.
Conclusions: To obtain response seems to be more important than
to achieve stable disease for both cytotoxic agents and EGFR TKIs,
although achieving stable disease is still valuable. The relationship
between survival and response or stable disease appears similar for
cytotoxic agents and EGFR TKIs.
Key Words: Stable disease, Response rate, Non-small cell lung
cancer, Second-line setting, Epidermal growth factor receptor, Ty-
rosine kinase inhibitors.
(J Thorac Oncol. 2006;1: 684–691)
In 1995, a meta-analysis demonstrated a modest survivalbenefit for cisplatin-based chemotherapy compared with
best supportive care as first-line therapy in patients with
locally advanced or metastatic non-small cell lung cancer
(NSCLC).1 Equal survival improvement is provided by in-
troducing several new agents with novel mechanisms and
significant activity against NSCLC such as taxanes, gemcit-
abine, and vinorelbine, when used in combination with a
platinum agent.2–4 However, most patients relapse following
platinum-based chemotherapy, leading to poor survival. Until
recently, the role of second-line chemotherapy was not well
defined because most patients had a poor performance status
by the time of relapse. However, as newer agents in combi-
nation with platinum agents have increased, the number of
patients with durable antitumor effects and the number of
patients for second-line chemotherapy have increased. There-
fore, second-line chemotherapy for advanced NSCLC is be-
coming increasingly important. Several chemotherapy agents
have been evaluated in the second-line setting. Among them,
docetaxel was the first agent to show a survival benefit and an
improvement in quality of life in two large phase III studies5,6
and has been approved as a second-line agent. A recent
randomized phase III study reported that pemetrexed (a
multitargeted antifolate, Alimta; Eli Lilly & Co., Indianapo-
lis, IN) had comparable activity and better symptom relief
than docetaxel.7 Both of these cytotoxic agents demonstrated
response rates of less than 10%, but both agents have dem-
onstrated survival benefits and an improvement in quality of
life. This indicates that it is important to achieve stable
disease and objective response for second-line cytotoxic
agents.
*Department of Medical Oncology, Kinki University School of Medicine,
Osaka, Japan; †Department of Epidemiology and Prevention, Aichi
Cancer Center Research Institute, Nagoya, Japan; ‡National Hospital
Organization, Kinki-Chuo Chest Medical Center; and §Kinki-Chuo On-
cology Meeting, Osaka, Japan.
Address for correspondence: Takayasu Kurata, MD, Department of Medical
Oncology, Kinki University School of Medicine, 377-2, Ohno-Higashi,
Osaka-Sayama, Osaka 589-8511, Japan. E-mail: kurata@hp.pref.hyogo.jp
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0107-0684
Journal of Thoracic Oncology • Volume 1, Number 7, September 2006684
The molecular targeted agents are attractive because
they promise to produce specific cytostatic action with a
resultant mild toxicity profile. In many tumors, overexpres-
sion of the epidermal growth factor receptor (EGFR) is
associated with a poor prognosis and chemoresistance,8,9 and
it is common in NSCLC.10–12 The low-molecular-weight
EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib
are the most advanced agents in clinical trials. The results of
a recent phase III study in the second-line setting showed that
erlotinib significantly improved survival compared with best
supportive care,13 although the overall response rate was only
9% on the erlotinib arm.
Because of their mechanism of action, it might be more
important to achieve stable disease for most molecular tar-
geted agents than for their cytotoxic counterparts. However,
evaluating stable disease in clinical trials is very difficult, as
patients with stable disease are not a homogeneous popula-
tion.
Based on this background, we hypothesized that not
only objective response but also stable disease could lead to
survival benefit, in particular, with molecular targeted agents.
Therefore, we retrospectively reviewed phase II and random-
ized phase III studies in the second-line setting using EGFR
TKIs and cytotoxic agents separately to evaluate our hypoth-
esis and ascertain whether the importance of achieving stable
disease was different between EGFR TKIs and cytotoxic
agents.
METHODS
Search and Selection for Trials
Data concerning response rates, rates of stable disease,
time to progression, and survival from all published studies
including phase II and randomized phase III studies assessing
the activity of EGFR TKIs and cytotoxic agents in the
second-line setting were identified electronically. We per-
formed the search for trials through a computer-based search
of the PubMed database using the following terms:
“NSCLC,” “chemotherapy (second or pretreated),” “ad-
vanced,” “not radiation,” “not adjuvant,” “randomized con-
trolled trial,” “human,” and “English,” in the chemotherapy
group. In the EGFR TKI group, we used the following terms:
“NSCLC,” “clinical trial,” “human,” “English,” and the name
of the EGFR TKI (e.g., gefitinib, referred from the review of
Wendy et al.14). All trials that had been reported by Septem-
ber 30, 2004, were targeted. However, because there was no
phase III study in the EGFR TKI group, only one abstract
from the Proceedings of the American Society of Clinical
Oncology, by Shepherd et al., was added. Among the re-
trieved studies, we excluded the trials that had missing
outcomes data. We also excluded phase I/II studies. When we
examined randomized phase III and randomized phase II
studies, if both arms (experimental and reference arms) in-
cluded cytotoxic agents or EGFR TKIs, both were included in
our analysis.
Statistical Analysis
All the analyses were performed with Stata version 8
(Stata Corp., College Station, TX). Multiple linear regression
analysis was applied to examine impacts on the proportion of
subjects who responded and achieved stable disease on sur-
vival (median survival time [MST] and time to progression
[TTP]). Scales in the models were percentages and months
for proportion of subjects and survival, respectively. Two
models were examined: model 1, including response rate and
stable disease rate or disease control rate (response rate plus
stable disease rate) as explanatory variables; and model 2,
including EGFR TKI usage (yes/no) and interaction terms
between EGFR TKI usage and response/stable disease rate or
disease control rate in addition to model 1. In the models,
each study was weighted by the number of subjects in an
intent-to-treat analysis setting in each study. Thereafter, we
chose model 1 based on the significance of interaction terms.
To further evaluate the impact of stable disease rate consid-
ering response rate, we chose a linear regression model for
residual (the observed median survival minus fitted median
survival in the response rate only model) as a dependent
variable with stable disease rate as a responsible variable.
This approach was applied to MST and TTP separately
(Figures 1 and 2). The statistical significance was defined as
a value of p  0.05, and adjustment for multiple comparison
was not considered because of the exploratory setting of this
study.
RESULTS
Study Characteristics
As a result of our search, we identified 219 references
and chose 45 trials for the chemotherapy group and nine trials
for the EGFR TKI group. The baseline characteristics of the
45 trials and nine trials are shown in Tables 1 and 2,
respectively. There are four randomized phase II and three
phase III studies for cytotoxic agents, and two randomized
phase II studies and one phase III study for EGFR TKIs. In
the analysis of cytotoxic agents, docetaxel, pemetrexed, other
agents, and many types of combination regimens are in-
cluded. In the analysis of EGFR TKIs, only monotherapies of
gefitinib and erlotinib were detected. The median number of
enrolled patients per study was 40 (range, 17–288) for the
cytotoxic agents and 103 (range, 31–488) for the analysis of
EGFR TKIs.
Median Survival Time
As shown in Table 3, both rate of stable disease and
response rate were statistically significanty associated with
MST in model 1 in the analysis that combined both cytotoxic
agents and EGFR TKIs. The coefficient 0.0375 (p  0.039)
for stable disease in model 1 indicates that MST increases by
0.0375 month for each 1% increase in stable disease rate.
Similarly, each 1% increase in response rate is associated
with an increase of 0.0744 month in MST (p  0.001). This
trend was similarly observed in model 2, which considered
the interaction between EGFR TKI treatment and two re-
sponse parameters. As interaction terms for EGFR TKI treat-
ment were not statistically significant, one may interpret that
the relationship between survival and response rate or stable
disease rate is not different between EGFR TKI and cytotoxic
chemotherapy. We therefore took model 1 as the model
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explaining associations between MST and response variables.
Figure 1A is a graphic presentation of observed MSTs cor-
responding to response rates with the fitted line. Figure 1B
presents how well the stable disease rate explains the residual
by the response rate only model. Both figures indicate that the
response rate and the stable disease rate significantly contrib-
ute to MST prolongation. The coefficient for the disease
control rate in model 1 was 0.05, indicating that a 1%
increase in the disease control rate prolongs MST by 0.05
month (p  0.001). Similar results regarding EGFR TKI
terms are listed in Table 3.
Time to Progression
Table 4 shows similar analyses as MST for TTP con-
sidering stable disease rate and response rate. Contrary to
MST analyses, only response rate showed a statistically
significant association with TTP. The coefficient 0.0954 (p
0.001) for response rate in model 1 indicates that TTP
increases 0.0954 month with each 1% increase in response
rates. Nonsignificant coefficient for stable disease rates indi-
cates lack of impact of this factor on TTP after response rate
has been accounted for. As interaction terms for EGFR TKI
treatment were not statistically significant, we took model 1
as the model explaining associations between TTP and re-
sponse variables. Figure 2 is a similar graphic presentation of
observed TTPs. Although Figure 2A shows that response rate
significantly influences the TTPs, there is no apparent asso-
ciation between TTPs and stable disease rate (Figure 2B). As
shown in Table 4, disease control rate was not significantly
associated with prolongation of TTP in model 1 and model 2.
EGFR TKI interaction terms were not statistically significant.
DISCUSSION
Since the introduction of molecular targeted agents
(especially epidermal growth factor receptor inhibitors) in
clinical trials in recent years, the importance of achieving
stable disease has become an important issue. For these
FIGURE 1. Scatterplot for MST and response/sta-
ble disease rates. (A) The observed MST corre-
sponding to the percentage of responders. (B) The
residuals (observed MST minus fitted MST in the
model for A). The figure indicates that both re-
sponse rate and stable disease rate significantly in-
fluence the prolongation of MST.
FIGURE 2. Scatterplot for TTP and response/stable
disease rates. (A) The observed median TTP corre-
sponding to the percentage of responders. (B) The
residuals (observed TTP minus fitted TTP in the
model for A). The figure indicates that the response
rate but not the stable disease rate significantly in-
fluences the prolongation of TTPs.
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TABLE 1. Characteristics of the Trials with Cytotoxic Agents in the Second-Line Setting for NSCLC
Author Phase Regimen No. (ITT) RR (%) SD (%) DCR (%) TTP (mo) MST (mo)
Stewart et al., 199615 II Paclitaxel  hydroxyurea 30 3 52 55 — 5
Georgoulias et al., 199716 II Paclitaxel  gemcitabine 26 29 25 54 — 8
Gridelli et al., 199917 II Gemcitabine 30 20 60 80 2.5 5.5
Crino et al., 199918 II Gemcitabine 83 19 31 50 — 8.5
Stathopoulos et al., 199919 II Paclitaxel  cisplatin 36 38.9 58.3 97.2 — —
Perng et al., 200020 II Docetaxel 14 28.6 — — 4.75 11.7
Mattson et al., 200021 II Docetaxel 72 13.8 29.3 43.1 2.4 7.2
Rosati et al., 200022 II Paclitaxel  cisplatin  gemcitabine 26 27 27 54 — 6
Sculier et al., 200023 II Gemcitabine 77 6 27.7 33.7 — 4.25
Gridelli et al., 200024 II Docetaxel 23 21.7 8.7 30.4 3 5
Hainsworth et al., 200025 II Gemcitabine  vinorelbine 55 16.4 43.6 60 — 6.5
Shepherd et al., 20005 III Docetaxel 55 5.5 47.3 52.8 — 7.5
Docetaxel 49 6.3 37.5 43.8 — 5.9
Fossella et al., 20006 III Docetaxel 125 10.8 33 43.8 2.1 5.5
Docetaxel 125 6.7 36 42.7 2.13 5.7
Vinorelbine/ifosfamide 123 0.8 31 31.8 1.98 5.6
Kosmas et al., 200126 II Gemcitabine  vinorelbine 43 33 37 70 6 8.5
Hainsworth et al., 200127 II Docetaxel  gemcitabine 40 10 48 58 6 6
Docetaxel  vinorelbine 23 0 40 40 5 8
Agelaki et al., 200128 II Vinorelbine  carboplatin 37 16 30 46 9 —
Kakolyris et al., 200129 II Cisplatin  irinotecan 44 22 20 42 8 8
Huisman et al., 200130 II Cisplatin  epirubicin 27 33 33 66 — 6.75
Pectasides et al., 200131 II Gemcitabine  vinorelbine 39 2.6 35.9 38.5 4.7 7.3
Lilenbaum et al., 200132 II Docetaxel 30 10 20 30 — 8
Kosmas et al., 200133 II Gemcitabine  docetaxel 40 22.5 32.5 55 4.5 7
Kakolyris et al., 200134 II Docetaxel  gemcitabine 32 15.6 34.4 50 7 6.5
Spiridonidis et al., 200135 II Docetaxel  gemcitabine 40 32.5 — — — 8.1
Juan et al., 200136 II Paclitaxel 40 39.47 39.47 78.94 5.4 9.7
Chen et al., 200237 II Docetaxel  gemcitabine 36 36.1 36.11 72.21 3.8 6.9
Gonzalez et al., 200238 II Irinotecan  vinorelbine 35 9 39 48 — 6.25
Rinaldi et al., 200239 II Topotecan  gemcitabine 35 11 23 34 — 7
Socinski et al., 200240 II Paclitaxel 62 8.1 37 45.1 — 5.2
Herbst et al., 200241 II Gemcitabine  vinorelbine 36 17 50 67 4.6 8.5
Sculier et al., 200242 II Paclitaxel 67 3 24 27 — 4.5
Thongprasert et al., 200243 II Docetaxel 34 10.7 47 57.2 — 5.95
Han et al., 200344 II Irinotecan  capecitabine 37 11.4 34.3 45.7 — 7.4
Chen et al., 200345 II Docetaxel  ifosfamide 17 31.3 62.5 93.8 4.6 8.3
Font et al., 200346 II Irinotecan  docetaxel 51 6 37 43 3 8
Chen et al., 200347 II Vinorelbine  cisplatin 22 9.5 61.9 71.4 3.7 7.6
Smit et al., 200348 II Pemetrexed 45 4.5 36 40.5 2.3 6.4
Pemetrexed 36 14.3 26 40.3 1.6 4
Chen et al., 200349 II Gemcitabine  vinorelbine 50 10 72 82 5 8.2
Dongiovanni et al., 200450 II Paclitaxel  gemcitabine 34 12 50 62 3 7
Georgoulias et al., 200351 II Irinotecan  gemcitabine 76 18.4 26.3 44.7 7.5 9
Irinotecan 71 4.2 25.3 29.5 5 7
Park et al., 200352 II Gemcitabine  vinorelbine 38 21 55 76 3.9 8.1
Serke et al., 200353 II Docetaxel 36 11 25 36 — 5.7
Hanna et al., 20037 III Pemetrexed 283 9.1 45.8 54.9 3.4 8.3
Docetaxel 288 8.8 46.4 55.2 3.5 7.9
Ceresoli et al., 200354 II Paclitaxel 53 15 21 36 7 —
Ardizzoia et al., 200355 II Docetaxel 42 10.5 23.5 34 — 3.2
Quoix et al., 200356 II Docetaxel 93 8.6 37.1 45.7 1.5 4.7
Docetaxel 89 7.4 49.4 56.8 2.1 6.7
ITT, intention to treat; RR, response rate; SD, stable disease; DCR, disease control rate; TTP, time to progression; MST, median survival time.
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agents, stabilization of disease without tumor shrinkage may
represent a meaningful benefit. This phenomenon has been
derived from two randomized phase II studies (Iressa Dose
Evaluation in Advanced Lung Cancer [IDEAL]-1 and IDE-
AL-2).60,61 In IDEAL-2, the median survival time of patients
achieving stable disease was 9.4 months versus 5.2 months
for those with progressive disease.61 Moreover, when sur-
vival and symptom improvement were analyzed together, the
median survival time for patients achieving stable disease
with symptom improvement was 12.8 months versus 4.8
months for those without symptom improvement.
In contrast, the importance of achieving stable disease
has been evaluated for cytotoxic agents. Docetaxel signifi-
cantly improved overall survival compared with best support-
ive care as second-line therapy despite the overall response
rate of only 6%.5 In this study, 42.7% of patients achieved
stable disease, which suggests that docetaxel also confers
clinical benefit by producing stable disease.
In this retrospective review, we investigated the rela-
tionship between response rates and survival benefit and
between the rates of stable disease and survival benefit in
second-line treatment of NSCLC using both cytotoxic agents
and EGFR TKIs. The more the rates of response and stable
disease increase, the more the improvement of overall sur-
vival is obtained in the analysis that combined both cytotoxic
agents and EGFR TKIs. However, as shown in Table 3, for
both cytotoxic agents and EGFR TKIs, the survival improve-
ment for a 1% increase in response rate is higher than for a
1% increase in stable disease rate. Moreover, for time to
progression, only response rate showed a statistically signif-
icant association with TTP. These results indicate that it is
more important to increase response rates than to achieve
TABLE 2. Characteristics of the Trials with EGFR TKIs in the Second-Line Setting for NSCLC
Author Phase Regimen No. (ITT) RR (%) SD (%) DCR (%) MST (mo)
Gridelli et al., 200057 II Gefitinib 59 3.4 11.8 15.2 4.7
Cappuzzo et al., 200358 II Gefitinib 63 15.9 42.8 58.7 4.1
Pallis et al., 200359 II Gefitinib 31 3 29 32 5.75
Fukuoka et al., 200360 II Gefitinib 103 17.5 35.9 53.4 7.6
Gefitinib 109 19.1 32.4 51.5 8
Kris et al., 200361 II Gefitinib 106 12 31 43 7
Gefitinib 115 9 31 40 6
Shepherd et al., 200462 III Erlotinib 488 9 35 44 6.7
Pe´rez-Soler et al., 200463 II Erlotinib 57 12.3 38.6 50.9 8.4
Cappuzzo et al., 200464 II Gefitinib 106 14.4 26.8 41.2 9.4
Cappuzzo et al., 200065 II Gefitinib 40 5 45 50 5
ITT, intention to treat; RR, response rate; SD, stable disease; DCR, disease control rate; TTP, time to progression; MST, median survival time.
TABLE 3. Multiple Regression Models for Predicting MST by Study Parameters
Model 1 Model 2
Coefficient SE p Value Coefficient SE p Value
Models evaluating SD/RR and interactions with EGFR TKIs use No. 1*
SD (%) 0.0375 0.0178 0.039 0.0500 0.0188 0.01
RR (%) 0.0744 0.0181 0.001 0.0669 0.0190 0.001
SD_EGFR interaction — — — –0.0967 0.0703 0.175
RR_EGFR_interaction — — — 0.1082 0.0591 0.073
EGFR TKI — — — 2.2773 2.5364 0.373
_cons 4.6156 0.6532 0.001 4.1579 0.7617 0.001
R2  0.214 R2  0.284
Models evaluating DCR and an interaction with EGFR TKIs use No. 2†
DCR (%) 0.0501 0.0119 0.001 0.0559 0.0132 0.001
DCR_EGFR_interaction — — — –0.0226 0.0466 0.629
EGFR TKI — — — 1.3146 2.0593 0.526
_cons 4.4323 0.6003 0.001 4.0573 0.7019 0.001
R2  0.19 R2  0.204
*Coefficients for SD and RR denote increase of MST in months for 1% increase in SD/RR (model 1).
†Coefficients for DCR denote increase of MST in months for 1% increase in DCR (model 1).
SD, stable disease; RR, response rate; DCR, disease control rate.
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stable disease to improve overall survival for both cytotoxic
agents and EGFR TKIs in the second-line setting, although
increasing stable disease rates is still valuable.
In our analysis, we could not find a significant differ-
ence between cytotoxic agents and EGFR TKIs in terms of
the relationship between survival and response and stable
disease rate, as interaction terms for EGFR TKI treatment
were not statistically significant. As a result, one may infer
that the effect on survival of increasing response rates and
stable disease rates is similar for cytotoxic agents and EGFR
TKIs. However, this interpretation requires cautions on two
points. First, our review contains many heterogeneous phase
II studies with greatly different registered numbers of cases,
and many heterogeneous patient characteristics with a greatly
different administered number of regimens before these stud-
ies. The method of evaluating response is also different.
These may possibly lead to a false conclusion. Moreover, the
main effect of EGFR TKI was large but not statistically
significant, indicating no evidence of a difference between
EGFR TKIs and cytotoxic agents in terms of survival. How-
ever, there are very few EGFR TKI studies included in this
review, and therefore the ability to detect such an effect may
be low. Second, evaluating stable disease in clinical trials is
very difficult, as patients with stable disease are not a homo-
geneous population. The Response Evaluation Criteria in
Solid Tumors study defined stable disease as the longest
diameter of tumor size from a less than 30% decrease to a less
than 20% increase.65 True disease stabilization inhibits tumor
growth and metastasis and may be associated with improve-
ment of survival, symptoms, and quality of life. However, it
is difficult to distinguish true stable disease from nonstable
disease. Therefore, it is crucial to classify a category of stable
disease in the future.
CONCLUSIONS
In conclusion, our review indicated that although it is
appropriate to adapt disease control rates to assess the effect
of agents in the second-line setting, which is a new concept
often used by clinical trials for molecular targeted agents, to
obtain response seems to be more important than to achieve
stable disease when new agents are developed, although
achieving stable disease is still valuable. The relationship
between survival and response and stable disease appears
similar for cytotoxic agents and EGFR TKIs.
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